Biocytogen and Acepodia Expand Partnership for Next-Generation Dual-Payload Bispecific ADCs
核心洞察
Biocytogen (搜索) and Acepodia (搜索) have entered into an option and license agreement to advance dual-payload bispecific antibody-drug conjugates (搜索) (BsAD2Cs) through structured evaluation of two BsADC programs.
The collaboration combines Biocytogen (搜索)'s RenLite® platform with Acepodia (搜索)'s Antibody-Dual-Drugs Conjugation (AD2C) technology to develop next-generation ADC designs that address limitations of conventional ADC programs.
Under the agreement terms, Biocytogen (搜索) is eligible to receive upfront option fees, milestone payments, and royalties, though specific financial details were not disclosed.
Biocytogen (搜索) Pharmaceuticals and Acepodia (搜索) announced an expanded collaboration through an option and license agreement designed to advance the development of dual-payload bispecific antibody-drug conjugates (搜索) (BsAD2Cs). The agreement grants Acepodia an option to obtain exclusive worldwide licenses for two bispecific antibody-drug conjugate (BsADC) programs from Biocytogen.
Strategic Partnership Framework
The collaboration builds upon the companies' recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs. Under the agreement terms, Biocytogen (搜索) is eligible to receive an upfront option fee and, upon Acepodia (搜索)'s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed.
"This new agreement builds upon our recent co-development collaboration with Acepodia (搜索), which has focused on the evaluation and selection of leading bispecific antibody and dual-payload ADC candidates," said Dr. Yuelei Shen, President and CEO of Biocytogen (搜索). "Based on the preclinical research conducted to date, we believe that the combination of Biocytogen's RenLite® platform with Acepodia's Antibody-Dual-Drugs Conjugation (AD2C) technology offers a compelling approach for the development of next-generation dual-payload bispecific ADCs."
Technology Platform Integration
The expanded partnership leverages complementary platform strengths to advance next-generation ADC designs with the potential to improve upon certain limitations observed in conventional ADC programs. Biocytogen (搜索)'s RenLite® platform is part of the company's proprietary RenMice® suite, which includes platforms for fully human monoclonal, bispecific, and multispecific antibody discovery, as well as bispecific antibody-drug conjugate discovery.
Acepodia (搜索)'s AD2C technology utilizes bio-orthogonal click chemistry approaches originating from Nobel Prize laureate Carolyn Bertozzi's lab. The platform is designed to improve safety and offer broad applicability across hematologic and solid tumor cancers (搜索), as well as autoimmune diseases.
"This option-based framework allows us to systematically assess how dual-payload conjugation strategies can be applied to bispecific antibody formats," said Sonny Hsiao, Ph.D., Chairman and CEO of Acepodia (搜索). "This collaboration reflects our focus on disciplined, data-driven AD2C platform expansion."
Development Progress
The joint team is progressing towards candidate evaluation milestones, with advancement decisions informed by ongoing research results and Acepodia (搜索)'s internal governance and option exercise criteria. Acepodia's conjugation platforms are designed for modular integration across antibodies, immune cells, and payload architectures, enabling flexible application across diverse therapeutic modalities.
Company Portfolios
Biocytogen (搜索) has established approximately 280 therapeutic antibody and multiple clinical asset co-development, out-licensing, and transfer agreements, along with over 50 target-nominated RenMice® licensing projects globally as of June 30, 2025. The company's partnerships include several collaborations with multinational pharmaceutical companies.
Acepodia (搜索) focuses on transforming cancer (搜索) and autoimmune disease (搜索) treatment with first-in-class immune cell engagers that deliver enhanced and targeted potency through multiple conjugation platforms. The company aims to bring next-generation therapies to patients underserved by current treatments by combining innovative science with a patient-centric vision.